On January 7, Yasheng Pharmaceutical and MD Anderson Cancer Center of the University of Texas, USA, announced a five-year strategic cooperation. Both parties will jointly conduct joint research in the field of oncology to promote the clinical development of five new cancer drug projects under development.
MD Anderson Cancer Center is the world's premier comprehensive cancer medical institution and is a world leader in cancer research and treatment.The cooperation aims to jointly develop a series of new cancer drugs based on Yasheng Pharmaceutical's unique protein-protein interaction drug discovery technology platform.The leukemia research team at MD Anderson Cancer Center will work with Yasheng Pharmaceutical to advance the clinical development of a number of apoptosis drugs and kinase-targeted drugs being developed by Yasheng Pharmaceutical. These candidates include Bcr-Abl inhibitor HQP1351, Bcl-2/XL inhibitor APG-1252, Bcl-2 selective inhibitor APG-2575, IAP inhibitor APG-1387 and MDM2-p53 inhibitor APG-115.The study will involve monotherapy and combination therapy with other agents for the treatment of a variety of hematologic malignancies.
This collaboration will make full use of the extensive experience of MD Anderson Cancer Center in translational medicine and clinical research, thereby accelerating the clinical development of collaborative drugs.This collaboration is expected to provide new therapeutic options for the treatment of various malignancies such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myeloproliferative neoplasms (MPN), and myelofibrosis.The collaboration will be led in person by Dr. Hagop Kantarjian, Director of the Leukemia Department at MD Anderson Cancer Center, whose previous research has led to more than 20 leukemia drugs being approved by the US Food and Drug Administration.
"MD Anderson Cancer Center has been working to develop and deliver more effective treatments for patients.This collaboration helps us explore new treatments for cancer.We will study this series of drug candidates and are interested in the novel mechanisms of action of these drugs.Dr. Kantarjian said.
Dr. Yang Dajun, Chairman of Yasheng Pharmaceutical, stated: "We are pleased to be able to reach this important collaboration with MD Anderson.We will work together and work closely with the MD Anderson team to accelerate the clinical development of related products and provide new treatment options for cancer patients worldwide as soon as possible."
About Yasheng Pharmaceutical
Yasheng Pharmaceutical is a China-based, global-oriented, original and innovative drug research and development company dedicated to the development of innovative drugs in the therapeutic areas of cancer, hepatitis B and aging-related diseases.The company has a self-developed protein-protein interaction targeted drug design platform.Yasheng Pharmaceutical's R & D product pipeline focuses on inhibitors of key proteins in the apoptosis pathway, restarting the apoptosis program of tumor cells by inhibiting BCL-2, IAP, or MDM2-p53, and second- and third-generation inhibitors of kinase mutants that appear in cancer therapy.The company's existing 8 new drug projects have entered Phase I-II clinical development in China, the United States and Australia.
About MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center, located in Houston, USA, is one of the most well-known cancer centers worldwide and is dedicated to providing care, research, education, and prevention to cancer patients.The sole mission of the institution is to end cancer for patients and their families around the world.MD Anderson Cancer Center is one of 49 comprehensive cancer centers designated by the National Cancer Institute (NCI).MD Anderson Cancer Center ranked first in cancer care in the "Best Hospitals" survey of the US News & World Report.Since the survey was conducted in 1990, the MD Anderson Cancer Center has been ranked in the top two cancer care hospitals in the United States each year, ranking first on 14 occasions in the past 17 years.MD Anderson Cancer Center received a Cancer Center Support Grant from the NCI, National Institutes of Health (P30 CA016672).